Amneal (AMRX) Director Gautam Patel Receives 283,632 Shares

What Happened
Gautam Patel, a director of Amneal Pharmaceuticals, received 283,632 shares of Amneal Class A common stock on August 10, 2026. The filing reports this as an award/other acquisition (code A); no per‑share price or direct cash value for these specific shares is disclosed. The shares were issued as part of Amneal’s acquisition of Kashiv BioSciences, in a transaction where Amneal paid $375,000,000 in cash (subject to adjustments) and issued 28,942,098 Class A shares to the sellers; the 283,632 shares were received by limited liability companies managed by Mr. Patel.

Key Details

• Transaction date: August 10, 2026 (reported on Form 4 filed Aug 12, 2026). Filing appears timely.
• Transaction type/code: Award/other acquisition (A).
• Shares received: 283,632 shares of Class A common stock.
• Price / value for these shares: Not separately disclosed (acquisition consideration described at aggregate level: $375M cash plus 28,942,098 shares).
• Shares owned after transaction: Not reported in the Form 4 provided.
• Footnote: Shares were issued pursuant to a Membership Interest Purchase Agreement related to Amneal’s purchase of 100% of Kashiv’s membership interests; the 283,632 shares were received by LLCs managed by the reporting person.

Context
This was not an open‑market purchase by the director but issuance of company stock as part of a corporate acquisition. Such issuance reflects deal consideration and/or allocation to affiliated entities rather than a personal cash buy, and may be subject to transfer restrictions or holding agreements. For investors, acquisition‑related issuances differ from insider market purchases as signals of insider conviction.